Kinase Inhibitor Collaboration

In September 2013 Selvita entered into strategic partnership with the US based biotech company – H3 Biomedicine. The aim of the joint project is development of innovative anticancer therapies with the use of small molecule inhibitors acting on two novel kinase targets associated with oncogenic signalling pathways in cancer.

Selvita reached first scientific/business milestone in May 2014. This collaboration was extended in September 2015, once again in September 2016 and is still ongoing.

In September 2013 Selvita entered into strategic partnership with the US based biotech company – H3 Biomedicine. The aim of the joint project is development of innovative anticancer therapies with the use of small molecule inhibitors acting on two novel kinase targets associated with oncogenic signaling pathways in cancer.